| |
Turnkey pharmaceutical manufacturing facilities and a 75% property tax exemption make expanding your bioscience business to Puerto Rico easier than ever. It's not what's next, it's where. Puerto Rico. 
|
|
Today’s Big NewsMay 22, 2024 |
|
Thursday, June 6, 2024 | 11am ET / 7am PT Assessment of antibody off-target reactivity is a regulatory requirement for clinical development. However, conventional screening methods are often ineffective in screening newer therapeutic modalities, and their predictive value for in vivo safety and toxicity is poor. Join us for a look at the new alternatives for success. Register now. 
|
|
| By Eric Sagonowsky Pfizer has made frequent headlines in recent months as it moves forward with a campaign to save $4 billion in annual costs by the end of this year. Now, the company has unveiled another savings drive that will run longer. |
|
|
|
By Nick Paul Taylor Biogen is placing a $1.15 billion bet on Chris Viehbacher’s diversification vision. The upfront payment has secured Biogen a deal to buy Human Immunology Biosciences (HI-Bio), a biotech that is preparing to advance an anti-CD38 monoclonal antibody into phase 3 in multiple rare immune-mediated indications. |
By Conor Hale According to a report from the San Diego Union-Tribune, the company will shutter operations at the end of this week, while laying off its remaining staff and leadership. |
By Andrea Park Though many pharmas have grand plans for digital disruption across their businesses, those plans are being disrupted themselves by monetary constraints, according to a recent report from Graphite Digital. |
|
Wednesday, June 12, 2024 | 11am ET / 8am PT If you are a company developing gene therapies, don’t miss this opportunity to learn about containment and aseptic filling solutions – how to prepare for fill finish early and ensure products are ready to ship immediately upon approval, providing life-saving drugs to patients as quickly as possible. Register now. 
|
|
By Annalee Armstrong The obesity business is cutthroat these days. AstraZeneca is taking no chances on missing out on the next big thing. The U.K. pharma is one of the first investors in a new biotech emerging today with $110 million to develop new therapies for healthy weight loss. |
By Fraiser Kansteiner The U.S. Department of Justice on Wednesday announced that Florida residents Pen Yu, 51, and Gregory Muñoz, 45, each pleaded guilty to one count of wire fraud conspiracy for their roles in a scheme to “fraudulently procure deeply discounted products” from Merck KGaA's MilliporeSigma and export them to China using faked export documents. |
By Zoey Becker After a fire broke out at a Novo Nordisk construction site last week, a separate fire emerged at the company's Denmark headquarters on Wednesday. The site was "not able to be saved," a spokesperson said. |
By Andrea Park A new survey from Dexcom suggests that living with Type 2 diabetes can have significant impacts not only on physical health but on mental health, too. |
By Helen Floersh GSK is doubling down on its efforts to make clinical trials more diverse, starting with defined enrollment targets and training its clinical R&D workforce on issues around diversity, equity, inclusion and bias in healthcare. |
By Kevin Dunleavy The more than 53,000 women in the U.S. who have filed injury lawsuits against Johnson & Johnson have added ammunition for their claims as new research indicates there is an association between long-term use of talcum-based powders and an increased risk of developing ovarian cancer. |
By Nick Paul Taylor Havas is rebranding its health network, launching new global agencies as part of a reshuffle that will put most of its groups into one of three offerings. |
By James Waldron A month after Evotec first alluded to a “strategic reset” to rebalance the company, the German biotech has revealed the end of its gene therapy aspirations. |
By Conor Hale The medical app developer Click Therapeutics will increase its digital reach by obtaining assets from the recently defunct Better Therapeutics, which began winding down its operations in March. |
By Conor Hale A digital pathology collaboration between Microsoft, the University of Washington and Providence health network aims to overcome a few of the obstacles to fully implementing artificial intelligence in the field of cancer diagnostics—and in some cases, through sheer scale. |
By Zoey Becker Pfizer downsized much of its operations at the site, where it first discovered Viagra, last year. Now, Asymchem has inked a lease to take over the facility. Asymchem will begin operations there this summer and employ some former Pfizer staffers. |
Fierce podcasts Don’t miss an episode |
| This week’s episode of “The Top Line” is the second part of a three-part series exploring the latest advancements in cell and gene therapy manufacturing. |
|
|---|
|
|
|
Wednesday, June 19, 2024 |10am ET / 7am PT Join us on Monday, June 19, 2024 for one hour all about oral cyclic peptide drug development. Smaller breakthroughs in our own labs demonstrate results worth registering for. 
|
|
Whitepaper Precision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
Whitepaper Learn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
Whitepaper This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
